Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
As these fluids flow past each other, they create a heat gradient in which heat is transferred and retained inside the body. The warm arterial blood transfers most of its heat to the cool venous blood now coming in from the outside. This conserves heat by recirculating it back to the body core. Since the arteries give up a good deal of their heat in this exchange, there is less heat lost through convection at the periphery surface. Another example is found in the legs of an Arctic fox treading on snow. The paws are necessarily cold, but blood can circulate to bring nutrients to the paws without losing much heat from the body. Proximity of arteries and veins in the leg results in heat exchange, so that as the blood flows down it becomes cooler, and does not lose much heat to the snow. As the (cold) blood flows back up from the paws through the veins, it picks up heat from the blood flowing in the opposite direction, so that it returns to the torso in a warm state, allowing the fox to maintain a comfortable temperature, without losing it to the snow. This system is so efficient that the Arctic fox does not begin to shiver until the temperature drops to −70 °C (−94 °F).
Michael George Hibberd (born 3 January 1990) is a former professional Australian rules footballer who played for the Melbourne Football Club and Essendon Football Club in the Australian Football League (AFL). A defender, 1.87 metres (6 ft 2 in) tall and weighing 94 kilograms (207 lb), Hibberd plays primarily on the half-back flank. After spending the 2008 season with the Dandenong Stingrays in the TAC Cup, he missed out on selection in the 2008 AFL draft, which saw him spend two seasons in the Victorian Football League (VFL) with the Frankston Football Club. After winning Frankston's best and fairest and the Fothergill–Round Medal as the VFL's most promising young player in 2010, he was recruited by the Essendon Football Club with the fourth selection in the 2011 pre-season draft. Hibberd made his AFL debut during the 2011 season and in the same year, he was forced to miss the second half of the year after a club-imposed suspension due to an assault charge. His next four years at the club saw him rewarded with the club rising star award and three top-ten finishes in the best and fairest count. After being suspended for the entire 2016 season due to his involvement in the Essendon supplements saga, he was traded to the Melbourne Football Club during the 2016 trade period. His first season with Melbourne saw him receive All-Australian honours and represent Australia in the International Rules Series.
== Weathering and biodegradion of oils within the marine environment == Environmental UCMs result from highly degraded petroleum hydrocarbons and once formed they can stay largely unchanged in sediments for many years. For example, in 1969 a diesel oil spill contaminated saltmarsh sediment within Wild Harbor River, US; by 1973 only a baseline hump was observed, which remained largely unchanged within the anaerobic sediment for the next 30 years. In a study of the potential for UCM-dominated oil to be further degraded, it was concluded that even using bacteria specifically adapted for complex UCM hydrocarbons in conjunction with nutrient enrichment, biodegradation rates would still be relatively slow. Bacterial degradation of hydrocarbons is complex and will depend on environmental conditions (e.g. aerobic or anaerobic, temperature, nutrient availability, available species of bacteria etc.).
Sources: en.wikipedia.org
Hence in each tier, pairs of genes are cloned into a destination fragment in the desired sequence, and these are subsequently assembled two at a time in successive tiers. Like MoClo, the Golden Braid standard alternates the BsaI and BpiI restriction enzymes between each tier. The development of the Golden Gate assembly methods and its variants has allowed researchers to design tool-kits to speed up the synthetic biology workflow. For example, EcoFlex was developed as a toolkit for E. Coli that uses the MoClo standard for its DNA parts, while a similar toolkit has also been developed for engineering the Chlamydomonas reinhardtii microalgae.
Groups such as the Bat Conservation International aim to increase awareness of bats' ecological roles and the environmental threats they face. This group called for Bat Appreciation Week from 24–31 October every year to promote awareness of the ecological importance of bats. In the United Kingdom, all bats are protected under the Wildlife and Countryside Acts, and disturbing a bat or its roost can be punished with a heavy fine. In Sarawak, Malaysia, "all bats" are protected under the Wildlife Protection Ordinance 1998, but species such as the hairless bat (Cheiromeles torquatus) are still eaten by the local communities. Humans have caused the extinction of several species of bat in modern history, the most recent being the Christmas Island pipistrelle (Pipistrellus murrayi), which was declared extinct in 2009. Many people put up bat houses to attract bats. The 1991 University of Florida bat house is the largest occupied artificial roost in the world, with around 450,000–500,000 residents. In Britain, thick-walled and partly underground World War II pillboxes have been converted to make roosts for bats, and purpose-built 'bat bridges' are occasionally built to mitigate damage to habitat from roads or other developments. Cave gates are sometimes installed to limit human entry into caves with sensitive or endangered bat species. The gates are designed not to limit the airflow and thus to maintain the cave's micro-ecosystem. In the United States, 35 of the 47 bat species roost on human-made structures, while 14 of them use bat houses.
Ibogaine is derived from the root of Tabernanthe iboga, a plant known to exhibit hallucinogenic effects in people who consume it. It is described as having a typical dose range of 1,000 to 1,500 mg orally, with these doses producing hallucinogenic effects, and a duration of 18 to 36 hours. However, lower doses like 200 to 400 mg orally are also active and said to be hallucinogenic. In addition, very low doses of ibogaine, like 8 to 50 mg orally, have been used and reported to produce stimulant or "antidepressant" effects. The onset of the drug is 1 to 3 hours and peak effects have been described as being reached after 2 hours. With full hallucinogenic doses, ibogaine is described as having three different phases of effects. The first phase is the acute or visionary phase, which onsets after 1 to 3 hours and has a duration of 4 to 8 hours; the second phase is the evaluative or introspective phase, which starts after 4 to 8 hours and has a duration of 8 to 20 hours; and the third phase is residual stimulation, which onsets after 12 to 24 hours and has a duration of 24 to 72 hours or longer. Each of these phases is described as having distinct qualitative effects. The visionary phase is a dream-like, conscious state called oneirophrenia. Visual effects are almost always present and are often described as films or slideshows. These may be accompanied by increases in long-term visual memory, resulting in autobiographical content. Other changes to sensation and perception may occur, including auditory hallucinations or distortions. Nausea and vomiting can be severe.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.